On August 29, 2018 ounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, reported that Jounce management will present at three upcoming investor conferences (Press release, Jounce Therapeutics, AUG 29, 2018, View Source;p=RssLanding&cat=news&id=2365252 [SID1234529173]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

H.C. Wainwright 20th Annual Global Investment Conference at 11:15 a.m. ET on Wednesday, September 5, 2018 in New York, NY
Baird 2018 Global Healthcare Conference at 3:45 p.m. ET on Wednesday, September 5, 2018 in New York, NY
2018 Wells Fargo Healthcare Conference at 11:30 a.m. ET on Thursday, September 6, 2018 in Boston, MA
A live webcast of each presentation will be available by visiting "Events and Presentations" in the Investors and Media section of Jounce’s website at www.jouncetx.com. A replay of the webcasts will be archived for 30 days following each presentation.

On August 29, 2018 Cambrex Corporation (NYSE: CBM), a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), reported that company management will present at the following investor conferences in September (Press release, Cambrex, AUG 29, 2018, View Source [SID1234529133]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

2018 Wells Fargo Healthcare Conference
Date: Wednesday, September 5, 2018
Time: 3:00 p.m. EDT
Location: Boston, MA

Morgan Stanley 16th Annual Global Healthcare Conference
Date: Friday, September 14, 2018
Time: 9:55 a.m. EDT
Location: New York, NY

The live audio webcast and slide presentations can be accessed from the Cambrex website at www.cambrex.com in the Investors section under "Webcasts & Presentations", and replays will be available for 90 days after the live events conclude.

On August 29, 2018 Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, reported that the Company’s management will present an overview and update of the Company’s business, and host investor meetings, at the 2018 Wells Fargo Healthcare Conference (Press release, Supernus, AUG 29, 2018, View Source [SID1234529356]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Date: Wednesday, September 5, 2018

Time: 11:25 a.m. ET
Place: The Westin Copley Place, Boston, Mass.

Investors interested in arranging a meeting with the Company’s management during this conference should contact the conference coordinator.

A live webcast of the presentation can be accessed by visiting ‘Events & Presentations’ in the Investor Relations section on the Company’s website at www.supernus.com. An archived replay of these webcasts will be available for 60 days after the conference on the Company’s website.

On August 29, 2018 Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) reported that the company is scheduled to participate in H.C. Wainwright 20th Annual Global Investment Conference in New York City (Press release, Ligand, AUG 29, 2018, View Source [SID1234529134]). Presentation takes place on Wednesday, September 5, 2018 at 12:30 p.m. Eastern time (9:30 a.m. Pacific time). John Higgins, CEO, and Matt Korenberg, CFO, will attend for Ligand.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be available on Ligand’s website at www.ligand.com. A replay of the presentation will be archived on the website for 30 days.

On August 28, 2018 Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer, reported that it will present a corporate overview at the 2018 Wells Fargo 13th Annual Healthcare Conference, being held on September 5-6 in Boston, MA (Press release, Aeglea BioTherapeutics, AUG 28, 2018, View Source [SID1234529097]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Wells Fargo Healthcare Conference

Aeglea BioTherapeutics Presentation Details

Date: Wednesday, September 5

Time: 10:50 am Eastern Time

Location: The Westin Copley Place, Boston, MA

Webcast: https://cc.talkpoint.com/well001/090518a_as/?entity=51_HGGS50C
To access the live and archived webcast of the presentation, please visit the Presentations & Events section of the Aeglea BioTherapeutics investor relations website. Please connect to the website at least 15 minutes prior to the presentation to allow for any software download that may be necessary. The replay of the webcast will be available for 30 days thereafter.

Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aeglea’s Compensation Committee of its Board of Directors has granted non-qualified stock options to purchase an aggregate of 41,000 shares of Aeglea’s common stock to four new employees under Aeglea’s 2018 Equity Inducement Plan. The 2018 Equity Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Aeglea (or following a bona fide period of non-employment), as an inducement material to such individual’s entering into employment with Aeglea, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules. The options have an exercise price of $10.28 or $10.54 per share, which is equal to the closing price of Aeglea’s common stock on August 24, 2018 or August 27, 2018, respectively. Each of the option awards vests as to 25% of the shares on the one-year anniversary of its grant, with the remainder of the shares vesting ratably over 36 months thereafter.